Navigation Links
MedWaves, Incorporated Announces Receipt of Taiwan Food and Drug Administration (TFDA) Certification to Import and Sell Its Patented AveCure™ Microwave Ablation System and Devices
Date:9/21/2011

SAN DIEGO, Sept. 21, 2011 /PRNewswire/ -- MedWaves' AveCure™ microwave coagulation-ablation (MWA) system uses microwave energy to volumetrically coagulate-ablate (destroy) soft-tissue lesions (abnormal structures) safely, effectively, precisely and with repeatability. The system has successfully treated over 1,000 patients worldwide, including lesions in bone, kidney, liver, lung and pancreas. The Company plans to bring its technology to treat lesions in other locations in the body. The Company's technology makes available treatment options for many cancer patients in either early or late stage and helps those who are running out of options.

Taiwan, with over 23 million in population, is one of 15 highly developed Asian countries in the region, an important market for MedWaves. As with other developed countries in the region, its cancer incidence rate is on the rise, and cancer remains the leading cause of death in Taiwan as its life expectancy continues to rise according to Taiwan Today, June 2011. The five most common types of cancer in 2008 were colon, liver, lung, breast and oral cancer according to Taiwan Central News Agency, April 2011. MedWaves is pleased to announce the receipt of TFDA certification to import and sell its products to help those in need. MedWaves will work in close coordination with its Taiwanese distributor-partners to schedule and conduct clinical evaluations for the sale of its AveCure™ system in key hospitals in Taiwan. Earlier this year, Hong Kong University published its successful treatment of tumors in the liver using the MedWaves AveCure™ microwave ablation system. The Hong Kong University has adopted the MedWaves™ AveCure system as a cancer treatment tool.

About AveCure™ Microwave Coagulation-Ablation System and Devices:

MedWaves AveCure™ Microwave Coagulation-Ablation System overcomes the limitations of other microwave and radiofrequency (RF) thermal ablation technologies to destroy lesions safely, effectively, precisely and with repeatability and uniformity. It is the only system approved in the market to provide clinicians with patented, fully integrated real-time temperature, both forward and reverse-power feedback to control energy delivery intelligently. The system, which consists of a generator, extension cable set, and an array of single-patient-use microwave-probe devices, enables the surgeons and interventional radiologists to treat soft-tissue lesions, such as tumors, safely and easily, with confidence. This single-patient-use device provides MedWaves with a continuous growth of revenue stream.

MedWaves AveCure™ Microwave Coagulation-Ablation System has also received USFDA approval for sales in the United States*, CE Mark for sales in the European Union, KFDA certification for import and sales in Korea, and SFDA certification for import and sales in China. Other received approval and certification announcements to follow.

About MedWaves, Incorporated

MedWaves, Inc., a United States company based in San Diego, California, develops innovative and proprietary microwave ablation technology for the minimally invasive coagulation-ablation products for soft tissue lesions, such as tumors. The Company's management team has extensive experience in the medical device marketplace. The Company's proprietary technology allows for the development of minimally invasive microwave antenna devices in a wide range of sizes, shapes and flexibility to meet the clinicians' requirements in the treatment of lesions in bone, kidney, liver, lung, pancreas and other locations in the body. MedWaves maintains California FDB and ISO 13485 Certifications to manufacture and distribute microwave coagulation-ablation system.

Contact Information:

Theodore Ormsby (email: tedormsby@avecure.com)  
Mobile: (858) 342-3331

George Leung, PhD (email: gleung@avecure.com)  
Mobile: (858) 705-5056

16760 W Bernardo Drive, San Diego, CA 92127        
Tel: (858) 946-0015              
Website: http://www.medwaves.com  

*The system is not intended for use in cardiac procedures.

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE MedWaves, Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Accuray Incorporated to Speak at UBS Global Life Sciences Conference
2. Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference
3. Accuray Incorporated to Host Investor Meeting at ASTRO 2011
4. Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement
5. ULURU Inc. Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor
6. Accuray Incorporateds CEO to Speak at Jefferies 2011 Global Healthcare Conference
7. Accuray Incorporated Announces HSR Clearance in Acquisition of TomoTherapy
8. Accuray Incorporated to Report Financial Results for Third Quarter of Fiscal 2011
9. Accuray Incorporated to Speak at 10th Annual Needham Healthcare Conference
10. Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
11. Proacta Incorporated and Yakult Honsha Announce an Agreement for the Collaborative Research, Development and Commercialization for Proactas PR509 Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , February 23, 2017 ... from increasing caseload for varicose veins in their body. ... globe are prompting the adoption of endovenous laser therapy ... global endovenous laser therapy market, published by ... of lifestyle choices and consequences of obesity have collectively ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in ... the month of February, patients who visit Hamlin Dental Group will receive a ticket ... two at the Cheesecake Factory. , Tickets are available for routine dental visits ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... in clinical trials, today announced that Premier Research, a leading clinical development service ... Clinical trials are becoming increasingly complex, due in part to an array of ...
(Date:2/23/2017)... ... 2017 , ... The Center for Autism and Related Disorders ... Research and Treatment (RI-CART) and Cinemaworld to present Sensory Friendly Films. The events ... films in an environment that accommodates their unique needs. , Launched in January, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... program today with a new Indiegogo campaign . Individuals are now able to ... the Los Angeles area, either as a participating patient or through an Indiegogo donation. ...
Breaking Medicine News(10 mins):